Sleep Disordered Breathing and Chronic Diseases-Schwartz et al.
INTRODUCTION
Sleep disordered breathing (SDB) is a highly prevalent condition with major consequences for cardiopulmonary health, public safety, healthcare utilization, and mortality. 1 SDB is characterized by repeated apneas and hypopneas causing frequent arousals, oxyhemoglobin desaturations, and excessive daytime sleepiness (EDS). 2 Clinical and epidemiologic studies in high-income countries (HICs) have demonstrated strong independent associations between SDB and cardiovascular outcomes, including prevalent and incident hypertension, coronary artery disease, heart failure, and incident stroke.
SDB also produces daytime hypersomnolence and neurocognitive dysfunction, 7, 8 which contribute to increased motor vehicle accidents, workplace injuries, and psychiatric disturbances. 3 Physical and mental sequelae of SDB account for a twofold increase in healthcare utilization [9] [10] [11] and loss of economic productivity 3, 12 in HICs. However, SDB prevalence, risk factors and association with chronic diseases in low-and middle-income countries (LMICs) are less well known.
Regional variations in social and biologic factors may have substantial effects on the prevalence of SDB in specific populations. In HICs, major risk factors for SDB are obesity, age, and male sex. 1 With the growing worldwide epidemic of obesity, SDB prevalence is also increasing in LMICs. In addition to obesity, racial and ethnic differences may be associated with an increased SDB prevalence. 1, 3 Moreover, a recent, large population-based study identified a high SDB prevalence in the United States Hispanic population (25.8% mild SDB, 9.8% moderate SDB, 3.9% severe SDB) but a very low rate of diagnosis (1.3%). 13 SDB prevalence and symptoms varied significantly across Hispanic/Latino subgroups; United States-based South Americans had slightly lower prevalence of SDB compared to other Hispanic/Latino groups but shorter sleep duration and more daytime sleepiness. Data from Latin America are limited to PLATINO, which observed a high prevalence of SDB symptoms and undiagnosed obstructive sleep apnea in four major Latin American metropolitan areas outside Peru. 14 Specifically, snoring was observed in 60%, witnessed apneas in 12%, excessive daytime sleepiness (EDS) in 16%, and the combination of nocturnal symptoms and EDS in 3%. Altituderelated hypoxia and underlying obstructive lung disease from household and ambient air pollution may also contribute to the relatively high prevalence of SDB in Latin America. 15, 16 Nevertheless, SDB in Latin America remains largely underdiagnosed and untreated.
We sought to characterize the prevalence and risk factors of SDB symptoms in four resource-limited settings in Peru. Because SDB symptoms are also associated with nocturnal hemodynamic, 17 metabolic, 18 and inflammatory stress, 19 we hypothesized SDB symptoms conferred an increased risk for comorbid chronic diseases.
METHODS

Study Setting
We investigated the prevalence and risk factors of SDB in adults aged 35 y or older across four Peruvian settings characterized by differences in altitude, urbanization, and air pollution: Pampas de San Juan de Miraflores, a periurban community of 60,000 people in Lima; Tumbes, on the northern coast of Peru, encompassing both agricultural and urbanizing communities totaling about 20,000 people; and Puno, a city and surrounding villages of approximately 150,000 people located in southeastern Peru at 3,825 m above sea level. Within Puno there are two separate sites: an urban setting located at the city center and a rural setting made up of surrounding communities.
All participants provided verbal informed consent after our research team read the entire informed consent document to them and any questions were answered. Informed consent was verbal because of high illiteracy rates. The study was approved by the Institutional Review Boards of Johns Hopkins University in Baltimore, MD, USA, and Universidad Peruana Cayetano Heredia and A.B. PRISMA in Lima, Peru.
Study Design
Recruitment began in September 2010 and was conducted until about 1,000 participants per site were enrolled. We enrolled a sex-and age-stratified random population-based sample in each site as previously described.
20 Eligibility criteria were: age 35 y or older, full-time resident of the study site, able to understand procedures and provide informed consent, not pregnant, without physical disability and without active pulmonary tuberculosis. Only one participant was enrolled per household. Trained field workers conducted a standardized questionnaire to assess sociodemographics and medical history, including cardiopulmonary risk factors and SDB symptoms, followed by a clinical assessment including blood pressure, weight, height, heart rate, spirometry, and pulse oximetry. Certified phlebotomists collected blood for processing in a centralized testing facility for serum lipids (including low-density lipoprotein [LDL] and high-density lipoprotein [HDL]), fasting glucose, fasting insulin, hemoglobin A1c (HbA1c), hemoglobin, and highly sensitive C-reactive protein (hs-CRP). Fasting blood samples were obtained and analyzed in a single facility and the quality of assays was checked with regular external standards and internal duplicate assays monitored by BioRad (www.biorad.com). Plasma glucose was measured using an enzymatic colorimetric method (GOD-PAP, Modular P-E/ Roche-Cobas, Mannheim, Germany) and hs-CRP using Tinaquant CRP-HS (Roche Diagnostics/Hitachi analyzer, Tokyo, Japan). Spirometry was conducted using the Easy-On-PC spirometer (ndd, Zurich, Switzerland) before and after 200 mcg of inhaled salbutamol via a spacer. Acceptability and reproducibility of spirometry followed standard guidelines.
20 Detailed information about measurement techniques and evaluation are reported elsewhere.
20
Modified Epworth Sleepiness Scale
A Spanish-language version of the Epworth Sleepiness Scale (ESS) was administered. Our questionnaires also included frequency and loudness of snoring and the occurrence of observed apneas. As previously noted, certain ESS questions are not applicable to the daily activities of many Peruvians. 21 In our cohort, large proportions of respondents reported sleepiness while driving (88.4%), sitting and reading (10.3%), and watching television (12.3%) as not applicable responses, which likely resulted from low rates of car and television ownership and high rates of illiteracy in Peru. In contrast, nearly all participants responded to the remaining Epworth questions: sitting inactive in a public place (99.1%), as a passenger in a motor vehicle (99.1%), afternoon nap (99.1%), sitting and talking (99.4%), and sitting quietly after lunch (99.4%). Accordingly, we constructed a modified ESS score (mESS) by adding the five Epworth questions with large response rates.
Definitions
We defined SDB symptoms as follows: habitual snoring was defined as self-reported snoring ≥ 3 nights per week; observed apneas were defined as pauses in breathing or choking during sleep reported by a spouse or bed partner to the participant; and excessive daytime sleepiness (EDS) was defined as mESS > 6 (out of 15 maximum possible points), which is proportional to the cutoff of 10 of 24 ESS points used in many studies. 22 We defined cardiovascular disease (CVD) as a self-reported diagnosis of heart disease or stroke; chronic obstructive pulmonary disease (COPD) as a postbronchodilator forced expiratory volume/forced vital capacity (FEV 1 /FVC) < 70% ; diabetes as a fasting plasma glucose > 126 mg/ dL or self-reported physician diagnosis and current use of antihyperglycemic medications 25 ; and hypertension as systolic blood pressure ≥ 140, diastolic blood pressure ≥ 90, or self-reported physician diagnosis and current use of antihypertensive medications. 26 Metabolic syndrome was defined according to the Joint Interim Statement criteria. 27 A chronic disease index was constructed as the sum of each of the following chronic conditions: CVD, COPD, depression, diabetes, and hypertension. Socioeconomic status (SES) was assessed using a wealth index based on current occupation, household income, assets, and household facilities. 28 
Biostatistical Methods
Our primary objectives were to estimate the prevalence of SDB symptoms, identify risk factors for each symptom, and determine whether SDB symptoms were associated with comorbid chronic diseases. The unadjusted prevalence of three SDB symptoms (habitual snoring, observed apneas, EDS) was calculated for each study setting. To compare characteristics of study participants with differing numbers of SDB symptoms, we conducted a nonparametric test for trend across ordered groups for continuous variables and chi-square tests for categorical variables. 29 For comparisons between unordered groups, we used Mann-Whitney U tests for continuous variables and chi-square tests for categorical variables. We used multivariable logistic regression to identify potential risk factors for each SDB symptom (habitual snoring, observed apneas, and EDS) including study site, altitude (sea-level sites in Lima and Tumbes versus highaltitude sites in Puno), sociodemographics (age, sex, BMI, and SES) and a priori selected cardiometabolic biomarkers (HbA1c, HDL/LDL ratio, and hs-CRP). To explore bivariate associations between SDB symptoms and chronic disease, we calculated the unadjusted prevalence of five chronic diseases (CVD, COPD, depression, diabetes, and hypertension) by number of SDB symptoms (0, 1, 2, or 3). We used multivariable logistic regression to calculate adjusted odds ratios (ORs) for each chronic disease by number of SDB symptoms, controlling for study site, age, sex, BMI, and SES. We used multivariable ordinal logistic regression to model chronic disease index as a function of SDB symptoms, study site, age, sex, BMI, and SES. We conducted statistical analyses in Stata 12.1 (StataCorp, College Station, TX, USA) and R (www.r-project.org).
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RESULTS
Participant Characteristics
Of 3,601 participants who were enrolled and completed questionnaires, 2,682 (74.5%) had complete data for analysis. There were 919 participants who were missing one or more of the following: 277 (7.7%) were missing information on SDB symptoms, 382 (10.6%) were missing sociodemographics or anthropometrics, 697 (19.4%) were missing chronic disease measures, and 699 (19.4%) were missing biomarkers. Participants with missing data were older (median 58.2 versus 54.1 y; P < 0.001), were more likely to be female (57.5% versus 49.4%; P < 0.001), had a lower median BMI (26.8 versus 27.4 kg/m 2 ; P = 0.003) and were more likely to have low SES (43.7% versus 29.8%; P < 0.001) than those with complete data. Among the 2,682 participants with complete data, those with the greatest number of SDB symptoms had a greater median age, BMI, waist circumference, HbA1c % and hs-CRP concentration and a greater proportion with metabolic syndrome; and had a lower median HDL/LDL ratio and hemoglobin concentration compared to participants with fewer symptoms (Table 1) .
Prevalence of SDB Symptoms
We found a high overall prevalence of habitual snoring Table S1 , supplemental material). For example, the unadjusted prevalence of habitual snoring was higher in sea-level populations than in those at high altitude (37.3% versus 16.1%, P < 0.001). In contrast, the unadjusted prevalence of observed apneas was higher at altitude than at sea level (28.6% versus 17.0%, P < 0.001). A different pattern was observed in the unadjusted prevalence of EDS: Lima had 
Risk Factors for SDB Symptoms
Variation in SDB symptoms across sites persisted when controlling for sociodemographics and biomarkers (Table 2) . Consistent with the pattern of unadjusted prevalences, adjusted ORs for habitual snoring were greatest at sea level (Lima and Tumbes), whereas adjusted ORs for observed apneas were greatest at high altitude (urban and rural Puno). Adjusted ORs for EDS were highest in Lima, intermediate in Puno, and lowest in Tumbes. In addition, SDB symptoms varied with sociodemographic factors, with distinct factors associated with each symptom. Habitual snoring was associated with older age, male sex, BMI, and high SES. Observed apneas were associated with BMI. EDS was associated with older age, female sex, and medium SES. None of the SDB symptoms were associated with any of our selected chronic disease biomarkers (HbA1c, HDL/LDL ratio, hs-CRP).
Nocturnal SDB symptoms and EDS were strongly associated with each other, controlling for sociodemographics and biomarkers, with a progressive increase in the odds for EDS with increasing number of nocturnal symptoms (Table S2 , supplemental material).
Associations between SDB Symptoms and Chronic Diseases
SDB symptom severity was strongly associated with comorbid chronic diseases. We observed a progressive increase in the unadjusted prevalence of CVD, depression, and hypertension with the number of SDB symptoms (Figure 2 , upper panels). Similar trends were observed in adjusted ORs of CVD (3.67, 95% CI 1.58-8.50, all three versus no SDB Figure 2 , lower panels). We also observed a step increase in unadjusted COPD prevalence and a trend toward increased adjusted odds of COPD in participants with all three versus no SDB symptoms (adjusted OR 1.42, 95% CI 0.55-3.68). No trend was observed in the unadjusted prevalence or adjusted odds of diabetes ( Figure S1 , supplemental material). The unadjusted prevalence and adjusted odds of any chronic disease increased progressively with the number of SDB symptoms (adjusted OR 4.24, 95% CI 2.27-7.90, all three versus no SDB symptoms). Both EDS and nocturnal SDB symptoms (i.e., habitual snoring and observed apneas) were independently associated with the overall risk of chronic disease. The overall burden of chronic disease increased progressively with both the severity of daytime sleepiness and with the number of nocturnal SDB symptoms, independent of study site and sociodemographics (Table 3) . Moreover, an increase in the total number of SDB symptoms was positively associated with the burden of chronic disease, controlling for study site and sociodemographics (Table 4 ). The presence of both nocturnal SDB symptoms and EDS was associated with a threefold increase in the odds of having an additional chronic comorbid condition (adjusted OR 3.57, 95% CI 2.18-5.84) versus participants with no SDB symptoms. Study site did not modify the association between SDB symptoms and chronic disease (P = 0.35 by likelihood ratio test).
To examine associations of comorbid conditions with nocturnal SDB symptoms, we conducted sensitivity analyses excluding EDS from the count of SDB symptoms. We found that the odds of having an additional comorbid condition increased by a factor of 1.23 (95% CI 1.03-1.46) for one nocturnal symptom and by a factor of 2.00 (95% CI 1.51-2.65) for two nocturnal symptoms versus no nocturnal symptoms.
DISCUSSION
This study offers a novel examination of SDB symptoms and chronic disease in a large cohort in four resource-limited settings in Peru. The overall prevalence of habitual snoring, observed apneas, and EDS were high, and symptoms varied by site and sociodemographic factors. Subjects living at altitude had greater odds of having observed apneas, whereas those at sea level were more prone to habitual snoring. Habitual snoring was associated with age, BMI, male sex, and high SES; observed apneas with BMI; and EDS with age, female sex, and medium SES, suggesting distinct SDB phenotypes in this population. We also demonstrated that nocturnal and daytime SDB symptoms are independently associated with increased risk of chronic disease. Specifically, the risk of CVD, depression, hypertension, and the overall burden of chronic disease increased progressively with the number of nocturnal and daytime SDB symptoms, independent of location and sociodemographic factors, suggesting a strong association between chronic disease and SDB.
Our findings suggest that multiple social and medical factors were associated with SDB symptoms including location and sociodemographic and anthropometric factors. As expected, recognized SDB risk factors such as age, BMI, and male sex 1 conferred increased risk of habitual snoring, whereas nocturnal apneas were primarily associated with BMI and altitude in our population. Unlike nocturnal SDB symptoms, the odds of EDS were diminished at altitude, greater in women, and elevated in lower socioeconomic strata. These findings suggest that EDS in Latino populations may be chiefly related to differences in total sleep time rather than to SDB. 13 For example, women could have reported greater degrees of daytime sleepiness than men due to greater sleep requirements 30 or disturbances in sleep and mood.
14,31 Consistent with our findings, ESS score has been found to be elevated in Peruvian transport workers who work additional nighttime hours or suffered from depression. 32 In addition to sleep restriction, sleep disruption in older participants can also contribute to EDS, particularly in those with SDB. 7, 33, 34 Thus, distinct nocturnal and daytime SDB symptom profiles in Peruvians likely reflect disturbances in sleep quantity and quality and related sociodemographic and biologic risk factors.
We also found that both nocturnal SDB symptoms and EDS were independent predictors of comorbid chronic disease. These symptoms have been demonstrated to predict sleep apnea in both clinical [35] [36] [37] and epidemiologic 38 populations in high-income countries as well as low-to middle-income Latin American countries. 14 The spectrum of nocturnal SDB symptoms, however, differed by altitude in our cohort. Residents at low altitude demonstrated a substantially greater prevalence of snoring, whereas those at high altitude exhibit a higher prevalence of apneas. These findings suggest that ambient hypoxia influences the expression of SDB at high altitude with a preponderance of central rather than obstructive sleep apnea, 39, 40 and that survey instruments should assess both snoring and apnea symptoms to capture the spectrum of SDB across altitudes. Furthermore, the high prevalence of nocturnal SDB symptoms in combination with EDS in our cohort suggests that SDB remains largely underdiagnosed and undertreated in resource-limited settings.
The burden of SDB is further highlighted by striking increases in chronic disease with progressive increases in SDB symptoms in our cohort. Of note, the combination of nocturnal and daytime symptoms was associated with a threefold increased risk of chronic disease. These findings are consistent with prior studies demonstrating similar associations between sleep apnea and cardiovascular morbidity and mortality.
1,3,41-43 Excess risk of chronic disease in sleep apnea may be mediated by cytokines 44 known to be pathogenic for sleep apnea, 45, 46 EDS, 45, 47, 48 metabolic syndrome, [49] [50] [51] [52] and cardiovascular disease. [53] [54] [55] [56] Alternatively, sleep apnea can trigger systemic inflammation 56, 57 leading to EDS and an increased risk of comorbid chronic disease. [57] [58] [59] Current evidence suggests that improvements in hypertension and cardiovascular risk profile with continuous positive airway pressure (CPAP) therapy may be confined to apneic patients with significant apnea and concomitant EDS. [60] [61] [62] Thus, the group with both nocturnal and daytime SDB symptoms has the greatest burden of chronic disease and will likely benefit most from early SDB recognition and treatment.
Several limitations should be considered in interpreting the findings of the current study. First, self-reported symptoms rather than objective measurements of SDB were used. Nevertheless, these symptoms are known to be associated with objective SDB in sleep study data in US Latinos 13 and Latin America 14 ; and we have confirmed population studies demonstrating that habitual snoring in the absence of nocturnal apneas or EDS has been associated with intermediate levels of comorbidity. 1 Moreover, the identical SDB symptom survey was applied across all sites, thereby minimizing any potential bias from differential classification. Any remaining nondifferential misclassification of participants' symptoms would likely lead us to underestimate the magnitude of the observed differences between sites (i.e., biasing results toward the null hypothesis of no difference). Second, our cross-sectional study design has delineated important links between nocturnal SDB symptoms, EDS, and chronic disease, but it cannot demonstrate causality. The CRONICAS cohort, however, is drawn from stratified random population-based samples in four locations, enhancing the generalizability of our findings and potential implications for public health. Moreover, longitudinal information collected will allow for future investigation of causal relationships between nocturnal SDB symptoms, EDS, and chronic disease. Finally, it is possible that cultural or linguistic barriers may have contributed to ascertainment bias, censored data and residual confounding, potentially diluting the strength of associations observed in our cohort. Nonetheless, we detected robust and stable effects across single variable and multivariable models.
CONCLUSIONS
In summary, our findings in a broad population-based sample across urban and rural Peruvian sites have demonstrated an overall high prevalence of SDB symptoms, and a strong independent association between SDB symptoms and comorbid chronic diseases. Of note, nocturnal symptoms varied by altitude with highlanders demonstrating greater odds of having observed apneas, and lowlanders more prone to habitual snoring. Finally, we found that the number of SDB symptoms was directly associated with chronic disease and with multiple comorbidities across four resource-limited settings in Peru. Our findings imply that in low-resource settings, patients with SDB symptoms should be targeted for early diagnosis and intervention to stem the development of chronic diseases such as cardiovascular disease and depression. 
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